Literature DB >> 21638092

HIPEC for peritoneal carcinomatosis: does an associated urologic procedure increase morbidity?

C Honoré1, A Souadka, D Goéré, F Dumont, F Deschamps, D Elias.   

Abstract

PURPOSE: To report the incidence of urinary tract procedures performed during complete cytoreductive surgery (CCRS) plus intraperitoneal chemotherapy, and to report the types of procedure, specific morbidity, risk factors, and treatment.
METHODS: Data were extracted from a prospective database of patients with malignant peritoneal disease treated with CCRS plus intraperitoneal chemotherapy who had undergone a resection or suture of the bladder, ureter, or kidney. Patients were eligible whatever the tumor origin.
RESULTS: Between 1994 and 2010, among the 598 patients treated with CCRS plus intraperitoneal chemotherapy, 48 (8%) had undergone a resection or suture in the urinary tract. Procedures included 4 nephrectomies, 19 partial cystectomies, 8 surgically repaired bladder injuries, and 18 ureteral resections. Postoperative mortality was 4% and morbidity was 41%. Specific complications included 6 urinary fistulas (12%), two among the 27 bladder sutures (7%) and four among the 18 ureteral sutures (22%) (P = NS). In the multivariate analysis, the risk factors for urinary fistula were severe preoperative malnutrition (P = 0.05, relative risk [RR] = 7.3) and extensive peritoneal disease (peritoneal cancer index ≥20, P = 0.05, RR = 8.3). Urinary fistulas had been treated nonsurgically in most of the cases.
CONCLUSIONS: Associated urinary tract procedures had occurred in 8% of the cases but did not greatly increase morbidity. Therefore, urinary tract involvement or injury are not contraindications to performing CCRS plus intraperitoneal chemotherapy. Fistulas had complicated only 12% of urinary sutures, mainly in cases of malnutrition or extensive peritoneal disease.

Entities:  

Mesh:

Year:  2011        PMID: 21638092     DOI: 10.1245/s10434-011-1820-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Cytoreductive Surgery and Peritonectomy Procedures.

Authors:  Sanket S Mehta; Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-03

2.  Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Konstantinos I Votanopoulos; Reese W Randle; Brandon Craven; Katrina R Swett; Edward A Levine; Perry Shen; John H Stewart; Majid Mirzazadeh
Journal:  Ann Surg Oncol       Date:  2013-11-12       Impact factor: 5.344

Review 3.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

4.  The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Grace Hwei Ching Tan; Nicholas B Shannon; Claramae Shulyn Chia; Lui Shiong Lee; Khee Chee Soo; Melissa Ching Ching Teo
Journal:  Asian J Urol       Date:  2017-10-04

5.  The outcomes of isolated ureteral resection and reconstruction in non-urologic cancer patients who underwent cytoreductive surgery (CRC) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Şevket Barış Morkavuk; Murat Güner; Mesut Tez; Ali Ekrem Ünal
Journal:  World J Surg Oncol       Date:  2019-12-26       Impact factor: 2.754

6.  Clinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy.

Authors:  Özgül Düzgün; Murat Kalın; Resul Sobay; Ömer Faruk Özkan
Journal:  Ther Adv Urol       Date:  2020-12-10

7.  Risk factors and clinical outcomes in patients undergoing cytoreductive surgery with concomitant ureteric reimplantation.

Authors:  Anais Alonso; Shoma Barat; Helen Kennedy; Meredith Potter; Nayef Alzahrani; David Morris
Journal:  Pleura Peritoneum       Date:  2021-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.